Orders from 120 EUR Free delivery from 250 EUR Ready for pickup dead drop: collect in 5 min Free parcel delivery from 250 EUR

Substances · Lysergamides

LSD-25

C20H25N3O CAS 50-37-3 Analytical reference material — not for human consumption
Preferred name
LSD-25
IUPAC name
(6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
Parent CAS number (reference)
50-37-3
Molecular formula
C20H25N3O
Molecular weight
323.4 g/mol
InChIKey
VAYOSLLFUXYJDT-RDTXWAMCSA-N
PubChem
CID 5761
Source
PubChem
Verified synonyms & catalog abbreviations
Lysergide Lysergic acid diethylamide LSD LSD25

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

LSD-25

Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist) Lysergamide
Verified PubChem & CAS Identity C20H25N3O · CAS 50-37-3 · CID 5761
Calibrated Physical Form Dissolved Liquid Solution (µg Calibrated)
≥98% Analytical Purity Verified 323.4 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

5-HT₂ₐ Perceptual & Visual Signaling Partial Agonist
5-HT₁ₐ / 5-HT₂c Serotonergic Modulation Active
D₂ / Adrenergic Dopaminergic / Somatic Tone Moderate

Prototypical ergoline partial agonist at 5-HT2A (Ki ~2.9 nM) with prolonged receptor 'lid' residence time (Wacker et al., Cell 2017) plus 5-HT1A and D2 signaling.

Biotransformation & Active Metabolites

Hepatic CYP2D6/3A4/1A2 oxidation to inactive 2-oxo-3-hydroxy-LSD (plasma T1/2 ~3.6 h).

Temporal Pharmacokinetics

Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist) — Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x).

  1. Onset 30–60 min
  2. Peak Window 2–4 h
  3. Total Window 8–12 h
  4. Residual / Half-Life 4–8 h residual wakefulness

Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x).

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
10–20 ug
Cognitive & Sensory

Subtle threshold receptor activity (Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist)).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
25–75 ug
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
75–150 ug
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
150–300 ug
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
300+ ug
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Lithium salts

Strongly documented to provoke acute tonic-clonic seizures, fugue states, and severe psychotic episodes with lysergamides.

Tramadol

Lowers seizure threshold alongside 5-HT2A excitation.

Elevated Hazard — Avoid

Cannabis & Strong Stimulants (Cathinones, Amphetamines, Cocaine)

Exponentially amplifies thought loops, tachycardia, anxiety, and acute paranoia.

Caution / Receptor Attenuation

SSRIs / SNRIs & Benzodiazepines

Chronic SSRIs and acute benzodiazepines markedly attenuate 5-HT2A perceptual effects.

Structural Isomer & Sibling Comparison

Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x).

Physicochemical Stability & Storage

Form: Clear, colorless calibrated liquid solution for microgram (µg) volumetric measurement. · Supplied pre-dissolved in analytical carrier; sensitive to chlorine/tap water.

Highly sensitive to UV light, heat, and chlorine; store airtight in amber glass under cold/refrigerated conditions.

Cross-Tolerance & Dependence Profile

Immediate rapid 5-HT2A receptor downregulation within hours, cross-tolerant with all tryptamines and phenethylamines; baseline sensitivity typically resets over 10–14 days. Non-addictive physiologically.

Comprehensive Analytical & Toxicological Monograph

LSD-25 ((6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; CAS 50-37-3, PubChem CID 5761) is a lysergamide reference compound (C20H25N3O, 323.4 g/mol) classified pharmacologically as a Reference Lysergamide (5-HT2A/1A/2C & D2 Agonist). Prototypical ergoline partial agonist at 5-HT2A (Ki ~2.9 nM) with prolonged receptor 'lid' residence time (Wacker et al., Cell 2017) plus 5-HT1A and D2 signaling. Hepatic CYP2D6/3A4/1A2 oxidation to inactive 2-oxo-3-hydroxy-LSD (plasma T1/2 ~3.6 h). In published observational and toxicological literature, threshold response is noted at 10–20 ug, light range at 25–75 ug, common reference range at 75–150 ug, strong intensity at 150–300 ug, and heavy/adverse territory at 300+ ug, with an onset of 30–60 min, peak window of 2–4 h, and total duration of 8–12 h (4–8 h residual wakefulness). Supplied strictly as calibrated dissolved liquid solution (never paper blotters); serves as the 1:1 molar benchmark for 1P-LSD (~0.85x), 1cP-LSD (~0.82x), and 1V-LSD (~0.79x). Critical contraindications include Lithium salts, Tramadol.

Chemical Architecture & Structural Profile

LSD-25 ((6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide) is a reference compound belonging to the Lysergamides class, characterized by the molecular formula C20H25N3O and a molar mass of 323.4 g/mol. The parent molecule is indexed under CAS registry number 50-37-3 and in the NCBI PubChem database as CID 5761 (Standard InChIKey: VAYOSLLFUXYJDT-RDTXWAMCSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), LSD-25 is indexed within the Lysergamides structural group. Toxicological notes (PsychonautWiki): extremely low toxicity relative to dose. Dependence liability (PsychonautWiki): non-addictive with a low abuse potential. Documented cross-tolerance class: psychedelics. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)